Takeda Pharmaceutical (TAK) Cash & Equivalents (2017 - 2026)

Takeda Pharmaceutical's Cash & Equivalents history runs 10 years deep, the most recent figure standing at $3.8 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 50.32% year-over-year to $3.8 billion; the TTM figure through Mar 2026 stood at $3.8 billion (up 50.32% YoY), while the FY2026 annual figure was $4.0 billion, up 56.36% from the prior year.
• Cash & Equivalents was $3.8 billion for Q1 2026 at Takeda Pharmaceutical, down from $4.3 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $7.3 billion in Q1 2022 to a low of $2.5 billion in Q1 2025.
• Historically, Cash & Equivalents has averaged $4.2 billion across 5 years, with a median of $3.8 billion in 2026.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents sank 44.83% in 2023, then jumped 50.7% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $6.0 billion in 2022, then tumbled by 39.99% to $3.6 billion in 2023, then slipped by 16.57% to $3.0 billion in 2024, then jumped by 41.32% to $4.3 billion in 2025, then dropped by 10.84% to $3.8 billion in 2026.
• The last three Cash & Equivalents figures came in at $3.8 billion (Q1 2026), $4.3 billion (Q4 2025), and $4.6 billion (Q3 2025), per Business Quant data.